Recent industry guidance aims to anchor rapid COVID-19 vaccine development in good manufacturing practice protocols.
Major bio/pharmaceutical companies and contract service providers leading the charge to bring COVID-19 vaccines to market are familiar with established good manufacturing practices (GMPs). To support manufacturers in the rush to develop a vaccine, FDA, in June 2020, released industry guidance highlighting the development and licensure of COVID-19 vaccines.
Read this article in BioPharm International’s Regulatory Sourcebook October 2020 eBook.
BioPharm International
eBook: Regulatory Sourcebook, October 2020
October 2020
Pages: 9–10
When referring to this article, please cite it as F. Mirasol, “GMPs Guide COVID-19 Vaccine Manufacturing," BioPharm International Regulatory Sourcebook eBook (October 2020).
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.